华润医药：华润博雅生物前三季度净利润 3.43亿元，同比下降16.8%

Core Viewpoint - China Resources Pharmaceutical (03320) announced that its subsidiary, China Resources Boya Bio (300294), achieved a total operating revenue of 1.474 billion RMB for the nine months ending September 30, 2025, representing a year-on-year growth of 18.4%. However, the net profit was 343 million RMB, showing a year-on-year decline of 16.8% [1] Summary by Category - Revenue Performance - China Resources Boya Bio reported total operating revenue of 1.474 billion RMB for the nine months ending September 30, 2025, which is an increase of 18.4% compared to the previous year [1] - Profitability - The net profit for the same period was 343 million RMB, reflecting a decrease of 16.8% year-on-year [1]